Overproduction of Tenascin‐C Driven by Lipid Accumulation in the Liver Aggravates Hepatic Ischemia/Reperfusion Injury in Steatotic Mice

Hiroyuki Kato, Sergio Duarte, Mary G. Miller, Ronald W. Busuttil, Ana J. Coito – 24 October 2018 – The purpose of this study was to assess the significance of tenascin‐C (Tnc) expression in steatotic liver ischemia/reperfusion injury (IRI). The critical shortage in donor organs has led to the use of steatotic livers in transplantation regardless of their elevated susceptibility to hepatic IRI. Tnc is an endogenous danger signal extracellular matrix molecule involved in various aspects of immunity and tissue injury.

Calnexin Depletion by Endoplasmic Reticulum Stress During Cholestasis Inhibits the Na+‐Taurocholate Cotransporting Polypeptide

Marion J.D. Robin, Monique D. Appelman, Harmjan R. Vos, Robert M. van Es, James C. Paton, Adrienne W. Paton, Boudewijn Burgering, Peter Fickert, Jarom Heijmans, Stan F.J. van de Graaf – 23 October 2018 – Cholestasis‐induced accumulation of bile acids in the liver leads to farnesoid X receptor (FXR)‐mediated transcriptional down‐regulation of the bile acid importer Na+‐taurocholate cotransporting protein (NTCP) and to induction of endoplasmic reticulum (ER) stress. However, whether ER stress affects bile acid uptake is largely unknown.

Pro: The Role of Albumin in Pre–Liver Transplant Management

Mauro Bernardi, Giacomo Zaccherini, Paolo Caraceni – 22 October 2018 – The wait‐list mortality of patients with decompensated cirrhosis awaiting liver transplantation remains elevated due to the occurrence of complications. Etiologic treatments improve patient survival and lower the incidence of complications when applied in compensated cirrhosis, but a decompensated disease does not improve or even progress despite a response to therapy in a substantial number of patients. Thus, disease‐modifying treatments that reduce the incidence of complications and improve survival are most needed.

Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Short‐Chain Fatty Acids in Experimental Cirrhosis

Oriol Juanola, Paula Piñero, Isabel Gómez‐Hurtado, Esther Caparrós, Rocío García‐Villalba, Alicia Marín, Pedro Zapater, Fabián Tarín, José M. González‐Navajas, Francisco A. Tomás‐Barberán, Rubén Francés – 22 October 2018 – Intestinal permeability to translocation of bacterial products is increased in cirrhosis. Regulatory T cells (Tregs) remain central to the interplay between the host and microbial milieu. We propose that Tregs are involved in promoting gut barrier integrity and a balanced interaction with gut microbiota–derived short‐chain fatty acids (SCFAs).

Improvement of Normothermic Ex Vivo Machine Perfusion of Rat Liver Grafts by Dialysis and Kupffer Cell Inhibition With Glycine

Joseph M. G. V. Gassner, Maximilian Nösser, Simon Moosburner, Rosa Horner, Peter Tang, Lara Wegener, David Wyrwal, Felix Claussen, Ruza Arsenic, Johann Pratschke, Igor M. Sauer, Nathanael Raschzok – 20 October 2018 – Normothermic ex vivo liver machine perfusion might be a superior preservation strategy for liver grafts from extended criteria donors. However, standardized small animal models are not available for basic research on machine perfusion of liver grafts.

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Jinhua Yan, Bin Yao, Hongyu Kuang, Xubin Yang, Qin Huang, Tianpei Hong, Yushu Li, Jingtao Dou, Wenying Yang, Guijun Qin, Huijuan Yuan, Xinhua Xiao, Sihui Luo, Zhongyan Shan, Hongrong Deng, Ying Tan, Fen Xu, Wen Xu, Longyi Zeng, Zhuang Kang, Jianping Weng – 19 October 2018 – To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine in this 26‐w

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Jinhua Yan, Bin Yao, Hongyu Kuang, Xubin Yang, Qin Huang, Tianpei Hong, Yushu Li, Jingtao Dou, Wenying Yang, Guijun Qin, Huijuan Yuan, Xinhua Xiao, Sihui Luo, Zhongyan Shan, Hongrong Deng, Ying Tan, Fen Xu, Wen Xu, Longyi Zeng, Zhuang Kang, Jianping Weng – 19 October 2018 – To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine in this 26‐w

Subscribe to